The start of the trial triggers a $5m milestone payment from AZ, which licensed AZD3152 from RQ Bio in May last year, and reinforces the financial position of the UK-based biotech to execute its four scientific programmes focused on viral diseases.
AZ’s trial will evaluate the safety and neutralising activity of AZD5156 – a combination of AZD3152 and cilgavimab – for the prevention of COVID-19 in patients with conditions that cause immune impairment and are therefore less likely to build an adequate protective response through vaccination.
